BridgeBio Pharma (BBIO) Operating Expenses (2018 - 2026)
BridgeBio Pharma (BBIO) posted Operating Expenses of $300.5 million for Q1 2026, up 2.29% sequentially from $293.7 million in Q4 2025, and up 35.96% YoY from $221.0 million in Q1 2025.
BridgeBio Pharma (BBIO) Operating Expenses (2018 - 2026) Analysis & Trends
BridgeBio Pharma has reported Operating Expenses for 9 years, with the latest figure at $300.5 million in Q1 2026.
- Quarterly Operating Expenses rose 35.96% year-over-year to $300.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 33.92% YoY) and the FY2025 annual result came in at $1.0 billion, up 25.85% from the prior year.
- Operating Expenses improved to $300.5 million in Q1 2026 per BBIO's latest filing, from $293.7 million in the prior quarter.
- Over five years, Operating Expenses peaked at $300.5 million in Q1 2026 and troughed at $128.0 million in Q1 2023.
- A 5-year average of $196.9 million and a median of $179.2 million in 2023 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2023 and 2024: Operating Expenses dropped 27.02% in 2023, then jumped 64.68% in 2024.
- Over 5 years, Operating Expenses stood at $131.1 million in 2022, then soared by 36.66% to $179.2 million in 2023, then advanced by 29.44% to $231.9 million in 2024, then advanced by 26.66% to $293.7 million in 2025, then gained by 2.29% to $300.5 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $300.5 million, $293.7 million, and $265.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | BridgeBio Pharma | 15.60 Bn | 14.89 Bn | 228.63 Mn | 350.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 350.76 Mn |
| Mar 31, 2026 | 300.47 Mn |
| Dec 31, 2025 | 293.74 Mn |
| Sep 30, 2025 | 265.90 Mn |
| Jun 30, 2025 | 244.84 Mn |
| Mar 31, 2025 | 221.01 Mn |
| Dec 31, 2024 | 231.91 Mn |
| Sep 30, 2024 | 194.48 Mn |
| Jun 30, 2024 | 177.71 Mn |
| Mar 31, 2024 | 210.78 Mn |
| Dec 31, 2023 | 179.16 Mn |
| Sep 30, 2023 | 161.78 Mn |
| Jun 30, 2023 | 147.74 Mn |
| Mar 31, 2023 | 127.99 Mn |
| Dec 31, 2022 | 131.10 Mn |
| Sep 30, 2022 | 129.45 Mn |
| Jun 30, 2022 | 153.92 Mn |
| Mar 31, 2022 | 175.37 Mn |
| Dec 31, 2021 | 178.50 Mn |
| Sep 30, 2021 | 151.84 Mn |